Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU

Berlin, February 6, 2023 – Bayer has submitted an application for market authorization to the European Medicines Agency (EMA) for aflibercept 8 mg in two major retinal eye diseases, neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).The submission is based on positive data from the phase III study…
Read More